PRINCETON, N.J., May 31, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, presented final results from the Phase 2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in women with recurrent cervical cancer at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. These data showed that ADXS-HPV was well-tolerated and that 22% (24/109) of the patients were long-term survivors (LTS) >18 months. 18% (16/91) of patients were alive for more than 24 months.
Help employers find you! Check out all the jobs and post your resume.
